Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
HIV Drug Project Would Aim For A Cure
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
Niche, Lackluster: Summing Up 2008 NCE Launches
CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
Intelence Demonstrates Continued Efficacy In HIV At 48-Weeks, Tibotec Reports
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Tibotec’s Etravirine NNRTI For HIV NDA Has Jan. 18 Action Date

Topics

Advertisement
UsernamePublicRestriction

Register

PS066764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel